U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104799) titled 'Momelotinib During and After HCT in Myelofibrosis' on July 29.
Brief Summary: This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Myelofibrosis
Hematopoietic Cell Transplantation (HCT)
Intervention:
DRUG: Momelotinib
Administered orally once per day during each 28-day cycle. This will start on day -7 (7 days before HCT) and continue for up to 13 cycles.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Massachusetts Ge...